S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,743.30 +1.32%

S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,743.30 +1.32%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

GILD

Gilead Sciences, Inc. NMS · GILD

$134.28 -2.02 (-1.48%)

Neutral · +0.86σ Grade C

+ Compare Open in Sniper

News · GILD

Full news feed →

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

GlobeNewswire Inc. · 1d ago

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

GlobeNewswire Inc. · 3d ago

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

The Motley Fool · 6d ago

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

The Motley Fool · 6d ago

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The Motley Fool · 10d ago

BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients

GlobeNewswire Inc. · 11d ago

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

Benzinga · 39d ago

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome

Benzinga · 46d ago

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More

The Motley Fool · 49d ago

Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases

GlobeNewswire Inc. · 60d ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire Inc. · 66d ago

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

GlobeNewswire Inc. · 68d ago

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

GlobeNewswire Inc. · 72d ago

PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

GlobeNewswire Inc. · 72d ago

Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

GlobeNewswire Inc. · 81d ago

Mag 7 Earnings Bonanza, Fed Await Stocks at Record Highs: What to Expect

Investing.com · 82d ago

Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy

Benzinga · 86d ago

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

GlobeNewswire Inc. · 86d ago

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

GlobeNewswire Inc. · 87d ago

Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight

GlobeNewswire Inc. · 93d ago

Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal

Benzinga · 102d ago

Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime

Investing.com · 103d ago

A Healthy Return: Drug Spin-off Nets Keymed Up To $320M

Benzinga · 107d ago

2 Defensive Dividend Payers Growing Fast on AI Demand

Investing.com · 109d ago

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Benzinga · 109d ago